The 10 references in paper R. Yagudina I., A. Kulikov U., N. Korolyova I., D. Ugrekhelidze T., Роза Ягудина Исмаиловна, Андрей Куликов Юрьевич, Надежда Королева Игоревна, Джумбер Угрехелидзе Тенгизович (2018) “Фармакоэкономика спастических форм детского церебрального паралича // Pharmacoeconomics of spastic cerebral palsy” / spz:neicon:vedomostincesmp:y:2015:i:3:p:60-64

1
Baranov AA, Namazova-Baranova LS, Kurenkov AL, еt al. A comprehensive assessment of motor functions in patients with cerebral palsy: a teaching aid. Moscow: Pediatrician, 2014; 84 p. (in Russian)
(check this in PDF content)
2
Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 14 (1): 45–66.
(check this in PDF content)
3
Kulikov AYu, Litvinenko MM. Methodological foundations of modeling in conducting pharmacoeconomic studies: different levels of complexity and different values of the obtained results. Pharmacoeconomics: theory and practice 2014; 2 (2): 9–22 (in Russian).
(check this in PDF content)
4
Zmanovskaya VA, Levitina EV, Popkov DA, Butorina MN, Pavlova OL. Prolonged use of the drug botulinum toxin type a, Dysport® in the complex rehabilitation of children with spastic forms of cerebral palsy. J Neurol Psychiatry. SS Korsakov 2014; 7: 33–6 (in Russian).
(check this in PDF content)
5
Khabriev RU, Kulikov AYu, Arinina EE. Methodological basis of pharmacoeconomic analysis. Moscow: Medicine, 2011; 128 p. (in Russian)
(check this in PDF content)
6
Kulikov AYu, Ugrekhelidze DT. Pharmacoeconomic study of botulinum toxin type A in treatment of post-stroke spasticity in the upper limb. Pharmacoeconomics: theory and practice 2014; 2 (3) 38–46 (in Russian).
(check this in PDF content)
7
Kulikov AYu, Ugrekhelidze DT. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Pharmacoeconomics: theory and practice 2015; 2 (3) (in press) (in Russian).
(check this in PDF content)
8
Kanovský P, Bares M, Severa S, Richardson A. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol 2009; 51: 6: 436–45.
(check this in PDF content)
9
Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am. 2006; 88 (1):161–70.
(check this in PDF content)
10
The RF Government decree of 28 November 2014 No 1273 "On the programme of state guarantees of free rendering to citizens of medical care for 2015 and on planning period 2016 and 2017" (in Russian). R E F E R E N C E S Куликов Андрей Юрьевич; Kulikov@expmed.ru
(check this in PDF content)